Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 4
2005 1
2006 3
2007 6
2008 1
2009 2
2010 3
2011 3
2012 3
2013 4
2014 6
2015 5
2016 1
2017 5
2018 7
2019 3
2020 6
2021 6
2022 12
2023 9
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Results by year

Filters applied: . Clear all
Page 1
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.
Mauro FR, Starza ID, Messina M, Reda G, Trentin L, Coscia M, Sportoletti P, Orsucci L, Arena V, Casaluci GM, Marasca R, Murru R, Laurenti L, Ilariucci F, Stelitano C, Mannina D, Massaia M, Rigolin GM, Scarfò L, Marchetti M, Levato L, Tani M, Arcari A, Musuraca G, Deodato M, Galieni P, Patrizi VB, Gottardi D, Liberati AM, Giordano A, Molinari MC, Pietrasanta D, Mattiello V, Visentin A, Vitale C, Albano F, Neri A, De Novi LA, De Propris MS, Nanni M, Del Giudice I, Guarini A, Fazi P, Vignetti M, Piciocchi A, Cuneo A, Foà R. Mauro FR, et al. Among authors: massaia m. Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116. Haematologica. 2023. PMID: 36632738 Free PMC article. Clinical Trial.
New drugs for treatment of multiple myeloma.
Bruno B, Rotta M, Giaccone L, Massaia M, Bertola A, Palumbo A, Boccadoro M. Bruno B, et al. Among authors: massaia m. Lancet Oncol. 2004 Jul;5(7):430-42. doi: 10.1016/S1470-2045(04)01511-6. Lancet Oncol. 2004. PMID: 15231250 Review.
Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myeloma.
Ziccheddu B, Giannotta C, D'Agostino M, Bertuglia G, Saraci E, Oliva S, Genuardi E, Papadimitriou M, Diamond B, Corradini P, Coffey D, Landgren O, Bolli N, Bruno B, Boccadoro M, Massaia M, Maura F, Larocca A. Ziccheddu B, et al. Among authors: massaia m. medRxiv [Preprint]. 2023 Dec 4:2023.12.04.23299287. doi: 10.1101/2023.12.04.23299287. medRxiv. 2023. PMID: 38106151 Free PMC article. Preprint.
Cost efficiency and effectiveness of biosimilar filgrastim in autologous transplant.
Giaccone L, Brunello L, Londono JS, Scaldaferri M, Cerrano M, Redoglia V, Omedè P, Lia G, Massaia M, Ferrero D, Cavallo F, Bringhen S, Leone S, Cattel F, Francisci T, Tassi V, Evangelista A, Boccadoro M, Bruno B. Giaccone L, et al. Among authors: massaia m. Bone Marrow Transplant. 2022 Feb;57(2):312-314. doi: 10.1038/s41409-021-01541-1. Epub 2021 Nov 30. Bone Marrow Transplant. 2022. PMID: 34848834 No abstract available.
83 results